Prof. Ali Mohammad Sharifi is a scholar with over 30 years of experience in Molecular Pharmacology at the Iran University of Medical Sciences and currently joined as a professor of regenerative Medicine in the Tissue Engineering Group at NOCERAL, department of Orthopedics Surgery, School of Medicine. He obtained his Ph.D. from the University of Glasgow in 1992 and in 2018, he further enriched his expertise by acquiring a Tissue Banking Diploma from the National University of Singapore. Throughout his career, Prof. Sharifi has undertaken international research, including working at McGill University in Canada and at Max Plank Institute in Germany. His research output includes over 100 publications in high-impact journals, along with several patented innovations. He has held various administrative and editorial roles in academia, and has served as a peer reviewer for numerous high-impact journals. His dedication to education is evident through his mentorship of undergraduate and postgraduate students, particularly Ph.D. candidates specializing in molecular medicine, tissue engineering, molecular pharmacology, and cell therapy.  Prof. Sharifi's research expertise involves the fields of cell therapy and regenerative Pharmacology, with a particular emphasis on translational medicine. His extensive body of work includes pioneering studies on pharmacological priming, therapeutic angiogenesis, and innovative strategies to enhance the effectiveness of stem cell therapy by manipulating HIF-1α stabilization, especially in the context of diabetes. Additionally, his